Toll Free: 1-888-928-9744

Anxiety Disorders - Pipeline Review, H1 2016

Published: Mar 30, 2016 | Pages: 284 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anxiety Disorders - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Anxiety Disorders - Pipeline Review, H1 2016', provides an overview of the Anxiety Disorders pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
- The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Anxiety Disorders

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Anxiety Disorders Overview 11 Therapeutics Development 12 Pipeline Products for Anxiety Disorders - Overview 12 Pipeline Products for Anxiety Disorders - Comparative Analysis 13 Anxiety Disorders - Therapeutics under Development by Companies 14 Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes 18 Anxiety Disorders - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Anxiety Disorders - Products under Development by Companies 23 Anxiety Disorders - Products under Investigation by Universities/Institutes 28 Anxiety Disorders - Companies Involved in Therapeutics Development 30 AbbVie Inc. 30 Ache Laboratorios Farmaceuticos S/A 31 Adamed Sp. z o.o. 32 Addex Therapeutics Ltd 33 Amorsa Therapeutics Inc. 34 Avineuro Pharmaceuticals, Inc. 35 Azevan Pharmaceuticals, Inc. 36 Bionomics Limited 37 Boehringer Ingelheim GmbH 38 C4X Discovery Holdings PLC 39 Catalyst Pharmaceutical Partners, Inc. 40 Edgemont Pharmaceuticals, LLC 41 Eisai Co., Ltd. 42 Eli Lilly and Company 43 F. Hoffmann-La Roche Ltd. 44 Gabather AB 45 GW Pharmaceuticals Plc 46 HolsboerMaschmeyer NeuroChemie GmbH 47 Humanetics Corporation 48 IntelGenx Corp. 49 Intra-Cellular Therapies, Inc. 50 INVENT Pharmaceuticals, Inc. 51 Marinus Pharmaceuticals, Inc. 52 Merz Pharma GmbH & Co. KgaA 53 MI.TO. Technology S.r.L. 54 Nemus Bioscience, Inc. 55 Neuralstem, Inc. 56 Neurelis, Inc. 57 NeuroNascent, Inc. 58 Newron Pharmaceuticals S.p.A. 59 Nippon Chemiphar Co., Ltd. 60 Novartis AG 61 Omeros Corporation 62 Otsuka Holdings Co., Ltd. 63 Pherin Pharmaceuticals, Inc. 64 Polleo Pharma Limited 65 Protagenic Therapeutics Inc. 66 Suda Ltd 67 Sumitomo Dainippon Pharma Co., Ltd. 68 Synchroneuron Inc. 69 Tonix Pharmaceuticals Holding Corp. 70 Trevena, Inc. 71 TRImaran Pharma, Inc. 72 Turing Pharmaceuticals AG 73 Vanda Pharmaceuticals Inc. 74 Anxiety Disorders - Therapeutics Assessment 75 Assessment by Monotherapy Products 75 Assessment by Target 76 Assessment by Mechanism of Action 80 Assessment by Route of Administration 83 Assessment by Molecule Type 85 Drug Profiles 87 18-MC - Drug Profile 87 acamprosate calcium SR - Drug Profile 88 ACH-36 - Drug Profile 90 ADN-2013 - Drug Profile 91 ADX-71441 - Drug Profile 92 ADX-71743 - Drug Profile 94 ADX-88178 - Drug Profile 95 alprazolam - Drug Profile 97 AM-3506 - Drug Profile 98 AVN-0189 - Drug Profile 100 AVN-101 - Drug Profile 101 AVN-628 - Drug Profile 102 BNC-210 - Drug Profile 103 brexpiprazole - Drug Profile 105 CPP-115 - Drug Profile 108 D-473 - Drug Profile 110 Drug for Post-Traumatic Stress Disorders - Drug Profile 111 Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile 112 Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 113 E-2508 - Drug Profile 114 evenamide - Drug Profile 115 fluvoxamine maleate - Drug Profile 116 Gaaba-001 - Drug Profile 117 ganaxolone - Drug Profile 118 HL-9001 - Drug Profile 120 IC-87201 - Drug Profile 121 iloperidone - Drug Profile 122 INV-107 - Drug Profile 124 INV-170 - Drug Profile 125 ITI-007 - Drug Profile 126 ketamine hydrochloride - Drug Profile 128 lorazepam - Drug Profile 129 lorazepam ER - Drug Profile 130 loxapine succinate - Drug Profile 131 LSN-2535717 - Drug Profile 132 LY-2607540 - Drug Profile 133 mavoglurant - Drug Profile 134 midazolam hydrochloride - Drug Profile 136 MRZ-8676 - Drug Profile 137 nabiximols - Drug Profile 138 NB-51R1 - Drug Profile 141 NEO-1940 - Drug Profile 142 NNI-351 - Drug Profile 143 NSI-189 - Drug Profile 144 OMS-527 - Drug Profile 146 Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile 148 PH-94B - Drug Profile 149 PT-00114 - Drug Profile 151 riluzole - Drug Profile 152 RO-646198 - Drug Profile 154 Rycal - Drug Profile 155 S-107 - Drug Profile 156 SCT-66 - Drug Profile 157 Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile 158 Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile 159 Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 160 Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 161 Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 162 Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 163 Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile 164 Small Molecules for Obsessive-Compulsive Disorder - Drug Profile 165 Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 166 Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 167 Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile 168 Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile 169 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 170 Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 172 Small Molecules to Agonize D2 and Inhibit MAO for Depression and Anxiety - Drug Profile 173 Small Molecules to Agonize Delta Opioid Receptor for Anxiety and Depression - Drug Profile 174 Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile 175 Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile 176 Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile 177 Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile 178 Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder - Drug Profile 179 Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 180 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 181 Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 182 Small Molecules to Modulate Mineralocorticoid Receptor for Depression and Anxiety - Drug Profile 183 Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder - Drug Profile 184 SRX-246 - Drug Profile 185 STX - Drug Profile 187 TNX-102 - Drug Profile 188 TPI-136117 - Drug Profile 190 TRV-250 - Drug Profile 191 UCM-765 - Drug Profile 193 URB-694 - Drug Profile 194 Vaccine for CNS Disorders - Drug Profile 195 VAD-1 - Drug Profile 196 VAD-2 - Drug Profile 197 vigabatrin - Drug Profile 198 VU-0431316 - Drug Profile 201 VU-0456810 - Drug Profile 202 ZL-006 - Drug Profile 203 Anxiety Disorders - Recent Pipeline Updates 204 Anxiety Disorders - Dormant Projects 248 Anxiety Disorders - Discontinued Products 263 Anxiety Disorders - Product Development Milestones 269 Featured News & Press Releases 269 Appendix 277 Methodology 277 Coverage 277 Secondary Research 277 Primary Research 277 Expert Panel Validation 277 Contact Us 277 Disclaimer 278
List of Tables
Number of Products under Development for Anxiety Disorders, H1 2016 18 Number of Products under Development for Anxiety Disorders - Comparative Analysis, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Number of Products under Development by Companies, H1 2016 (Contd..1) 21 Number of Products under Development by Companies, H1 2016 (Contd..2) 22 Number of Products under Development by Companies, H1 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Comparative Analysis by Late Stage Development, H1 2016 25 Comparative Analysis by Clinical Stage Development, H1 2016 26 Comparative Analysis by Early Stage Development, H1 2016 27 Comparative Analysis by Unknown Stage Development, H1 2016 28 Products under Development by Companies, H1 2016 29 Products under Development by Companies, H1 2016 (Contd..1) 30 Products under Development by Companies, H1 2016 (Contd..2) 31 Products under Development by Companies, H1 2016 (Contd..3) 32 Products under Development by Companies, H1 2016 (Contd..4) 33 Products under Investigation by Universities/Institutes, H1 2016 34 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 35 Anxiety Disorders - Pipeline by AbbVie Inc., H1 2016 36 Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 37 Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H1 2016 38 Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H1 2016 39 Anxiety Disorders - Pipeline by Amorsa Therapeutics Inc., H1 2016 40 Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016 41 Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H1 2016 42 Anxiety Disorders - Pipeline by Bionomics Limited, H1 2016 43 Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H1 2016 44 Anxiety Disorders - Pipeline by C4X Discovery Holdings PLC, H1 2016 45 Anxiety Disorders - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 46 Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2016 47 Anxiety Disorders - Pipeline by Eisai Co., Ltd., H1 2016 48 Anxiety Disorders - Pipeline by Eli Lilly and Company, H1 2016 49 Anxiety Disorders - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 50 Anxiety Disorders - Pipeline by Gabather AB, H1 2016 51 Anxiety Disorders - Pipeline by GW Pharmaceuticals Plc, H1 2016 52 Anxiety Disorders - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2016 53 Anxiety Disorders - Pipeline by Humanetics Corporation, H1 2016 54 Anxiety Disorders - Pipeline by IntelGenx Corp., H1 2016 55 Anxiety Disorders - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 56 Anxiety Disorders - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 57 Anxiety Disorders - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 58 Anxiety Disorders - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 59 Anxiety Disorders - Pipeline by MI.TO. Technology S.r.L., H1 2016 60 Anxiety Disorders - Pipeline by Nemus Bioscience, Inc., H1 2016 61 Anxiety Disorders - Pipeline by Neuralstem, Inc., H1 2016 62 Anxiety Disorders - Pipeline by Neurelis, Inc., H1 2016 63 Anxiety Disorders - Pipeline by NeuroNascent, Inc., H1 2016 64 Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H1 2016 65 Anxiety Disorders - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 66 Anxiety Disorders - Pipeline by Novartis AG, H1 2016 67 Anxiety Disorders - Pipeline by Omeros Corporation, H1 2016 68 Anxiety Disorders - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 69 Anxiety Disorders - Pipeline by Pherin Pharmaceuticals, Inc., H1 2016 70 Anxiety Disorders - Pipeline by Polleo Pharma Limited, H1 2016 71 Anxiety Disorders - Pipeline by Protagenic Therapeutics Inc., H1 2016 72 Anxiety Disorders - Pipeline by Suda Ltd, H1 2016 73 Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 74 Anxiety Disorders - Pipeline by Synchroneuron Inc., H1 2016 75 Anxiety Disorders - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 76 Anxiety Disorders - Pipeline by Trevena, Inc., H1 2016 77 Anxiety Disorders - Pipeline by TRImaran Pharma, Inc., H1 2016 78 Anxiety Disorders - Pipeline by Turing Pharmaceuticals AG , H1 2016 79 Anxiety Disorders - Pipeline by Vanda Pharmaceuticals Inc., H1 2016 80 Assessment by Monotherapy Products, H1 2016 81 Number of Products by Stage and Target, H1 2016 83 Number of Products by Stage and Mechanism of Action, H1 2016 87 Number of Products by Stage and Route of Administration, H1 2016 90 Number of Products by Stage and Molecule Type, H1 2016 92 Anxiety Disorders Therapeutics - Recent Pipeline Updates, H1 2016 210 Anxiety Disorders - Dormant Projects, H1 2016 254 Anxiety Disorders - Dormant Projects (Contd..1), H1 2016 255 Anxiety Disorders - Dormant Projects (Contd..2), H1 2016 256 Anxiety Disorders - Dormant Projects (Contd..3), H1 2016 257 Anxiety Disorders - Dormant Projects (Contd..4), H1 2016 258 Anxiety Disorders - Dormant Projects (Contd..5), H1 2016 259 Anxiety Disorders - Dormant Projects (Contd..6), H1 2016 260 Anxiety Disorders - Dormant Projects (Contd..7), H1 2016 261 Anxiety Disorders - Dormant Projects (Contd..8), H1 2016 262 Anxiety Disorders - Dormant Projects (Contd..9), H1 2016 263 Anxiety Disorders - Dormant Projects (Contd..10), H1 2016 264 Anxiety Disorders - Dormant Projects (Contd..11), H1 2016 265 Anxiety Disorders - Dormant Projects (Contd..12), H1 2016 266 Anxiety Disorders - Dormant Projects (Contd..13), H1 2016 267 Anxiety Disorders - Dormant Projects (Contd..14), H1 2016 268 Anxiety Disorders - Discontinued Products, H1 2016 269 Anxiety Disorders - Discontinued Products (Contd..1), H1 2016 270 Anxiety Disorders - Discontinued Products (Contd..2), H1 2016 271 Anxiety Disorders - Discontinued Products (Contd..3), H1 2016 272 Anxiety Disorders - Discontinued Products (Contd..4), H1 2016 273 Anxiety Disorders - Discontinued Products (Contd..5), H1 2016 274


List of Figures
Number of Products under Development for Anxiety Disorders, H1 2016 18 Number of Products under Development for Anxiety Disorders - Comparative Analysis, H1 2016 19 Number of Products under Development by Companies, H1 2016 20 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Comparative Analysis by Clinical Stage Development, H1 2016 26 Comparative Analysis by Early Stage Products, H1 2016 27 Assessment by Monotherapy Products, H1 2016 81 Number of Products by Top 10 Targets, H1 2016 82 Number of Products by Stage and Top 10 Targets, H1 2016 82 Number of Products by Top 10 Mechanism of Actions, H1 2016 86 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 86 Number of Products by Routes of Administration, H1 2016 89 Number of Products by Stage and Routes of Administration, H1 2016 89 Number of Products by Molecule Types, H1 2016 91 Number of Products by Stage and Molecule Types, H1 2016 91

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposable

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify